Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon

KHE: kaposiform hemangioendothelioma KMP: Kasabach-Merritt phenomenon INTRODUCTION Kaposiform hemangioendothelioma (KHE) was first described by Zuckerberg et al in 1992. KHE is defined as a rare, locally aggressive infiltrative vascular neoplasm that typically occurs during infancy and childhood. KHE generally originates on the skin as a distinctive… CONTINUE READING